Cellis

🚀 Discover How Our Technology Works! 🎥 To give you a closer look at our breakthrough approach, we’ve created a short video showcasing our innovative macrophage-based therapy. Watch and see how we're redefining cancer treatment! #CellTherapy #Macrophages #CancerResearch #Innovation #Cellis

We’re pleased to announce that Prof. Magdalena Król, CSO of Cellis, will be presenting in the Emerging Biotech Company category at Swiss Biotech Day 2025—a leading global platform for innovation and collaboration in life sciences. Join us on: May 6 | 15:45–16:00 | Room: Singapore Presentation Title: Revolutionizing Solid Tumors Treatment with Macrophage Drug Conjugates Magdalena will introduce our proprietary Macrophage Drug Conjugates (MDC) and the breakthrough TRAIN mechanism—a Trojan Horse–like strategy that enables potent, sustained immune activation and tumor regression with minimal drug exposure. We look forward to connecting with fellow researchers, partners, and biotech leaders in Basel. #SwissBiotechDay #Immunotherapy #Macrophages

Cellis will be present at the upcoming AACR Annual Meeting, taking place April 25–30 in Chicago, where leaders in oncology research gather to shape the future of cancer treatment. We’re proud to contribute to this global conversation with new developments in macrophage-based therapies. We invite you to visit our three poster presentations: PO.ET02.08 Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors April 28, 9:00 AM – 12:00 PM | Section 23 PO.CL06.01 Macrophage-ferritin-drug conjugates: a novel approach to overcome glioblastoma drug resistance and induce long-term tumor immunity April 28, 2:00 PM – 5:00 PM | Section 27 PO.IM01.16 Macrophage-based immunotherapy of platinum-resistant ovarian cancer April 29, 2:00 PM – 5:00 PM | Section 40 We look forward to insightful discussions and potential collaborations in Chicago. #AACR2025 #MacrophageTherapy #ImmunoOncology #CellTherapy

Solid tumors present a major therapeutic challenge due to limited drug penetration, immune suppression, and treatment resistance. But what if we could use macrophages, the only immune cells that naturally infiltrate hypoxic tumor regions, to deliver therapies directly to cancer cells? A recent BioWorld article explores the potential of macrophage-drug conjugates (MDCs) in overcoming these barriers and enhancing solid tumor treatment. The preclinical results are promising, offering a new direction for immuno-oncology and targeted drug delivery. Read more about this approach here: 🔗 https://lnkd.in/dzjRfbXQ #CancerResearch #Macrophages #ImmunoOncology #Biopharma #CellTherapy

A recent article in Drug Discovery World highlights our research published in Nature Communications, showcasing the potential of macrophage-based therapies for solid tumors. Our MDC platform harnesses macrophages to deliver anti-cancer drugs via the TRAIN mechanism, offering a novel and clinically viable approach. #Macrophages #Oncology #CellTherapy #CancerResearch #Cellis

Cellis was present at the Inaugural AACR Immuno-Oncology (IO) Conference 2025, where leaders in cancer immunotherapy, inflammation, and cellular therapies gathered to discuss the latest advancements in the field. This conference, organized by the American Association for Cancer Research (AACR), highlighted cutting-edge research, including late-breaking clinical trials, immune-based cancer treatments, and novel therapeutic strategies. The discussions and collaborations at AACR IO are invaluable as we continue advancing our macrophage-based therapies to transform solid-tumor treatment. A big thank you to AACR Journals and the conference organizers for hosting such a pivotal event in the world of immuno-oncology. #CancerResearch #ImmunoOncology #CellTherapy #AACRIO2025 #Biotech #Immunotherapy

Cellis has been featured in Nature's Biopharma Dealmakers, showcasing our innovative macrophage–drug conjugate (MDC) platform and its potential to transform solid-tumor cell therapy. The article highlights the unique advantages of our MDC technology, its dual mechanism of action, and its potential to overcome key challenges in solid-tumor treatment. It also outlines our progress toward the clinic, with first-in-human trials of MDC-735 planned for 2025 in collaboration with Stanford University and University Hospital Zürich. If you're interested in the future of oncology and how Cellis is tackling solid tumors with an "off-the-shelf" cell therapy, this is a must-read. 📖 Read the full article: https://lnkd.in/dKS6x5Q5 #Nature #BPDM #BiopharmaDealmakers #Biopharma #CellTherapy #CancerResearch #Macrophages #Immunotherapy #Oncology

Macrophage–drug conjugates (MDCs) offer a breakthrough in solid-tumor therapy by delivering targeted anticancer drugs with promising preclinical efficacy. #AdFeature with Cellis

A Decade of Research Culminates in a Landmark Discovery – Published Today in Nature Communications! On World Cancer Day, a day dedicated to the global fight against cancer, we at Cellis are incredibly proud to mark this occasion with a major scientific milestone: our latest research has just been published in Nature Communications! This paper represents 10 years of relentless research, bringing us closer to a future where macrophage-based therapies can revolutionize the treatment of solid tumors. 🔬 What’s the breakthrough? Our study introduces the Macrophage-Drug Conjugate (MDC) platform, a novel approach harnessing macrophages to deliver anti-cancer drugs to tumors via the TRAIN mechanism (TRAnsfer of Iron-binding protein). By leveraging the natural biology of macrophages and their interaction with cancer cells, we demonstrate a powerful strategy for targeted therapy—one that is both effective and clinically viable. 👩🔬👨🔬 Meet the brilliant minds behind this work: Bartłomiej Taciak, Maciej Białasek, Małgorzata Kubiak, Ilona Marszałek, Małgorzata Górczak, Olha Osadchuk, Daria Kurpiel, Damian Strzemecki, Karolina Barwik, Marcin Skórzyński, Julia Nowakowska, Waldemar Lipiński, Łukasz Kiraga, Jan Brancewicz, Robert Klopfleisch, Lukasz Krzeminski, Emilia Górka, Anna Smolarska, Irena Barbara Pruszyńska, Małgorzata Siemińska, Jakub Guzek, Jan Kutner, Marlena Kisiała, Krzysztof Woźniak, Giacomo Parisi, Roberta Piacentini, Luca Cassetta, Lesley M. Forrester, Lubomir Bodnar, Tobias Weiss, Alberto Boffi, Paulina Kucharzewska, Tomasz Rygiel & Magdalena Król. Read the full paper here: https://lnkd.in/dctZdK-4 As we observe World Cancer Day, it’s immensely satisfying to contribute meaningful progress to the fight against cancer. Our work doesn’t stop here—this is just the beginning. Stay tuned! #WorldCancerDay #Cellis #MacrophageTherapy #TRAINmechanism #NatureCommunications #CancerResearch